European Biotechnology Magazine

Kurma Partners has closed Biofund IV at €215 million, giving European biotech founders a meaningful new source of capital even though the vehicle came in below the €250 million target Kurma set when it launched the fund in October 2024. At first close, Kurma had raised €140 million and said Biofund IV would back 16 to 20 companies, building on the strategy it used in earlier ...

CryptiVax-1001 is set to enter first-in-human testing in advanced high-grade serous ovarian cancer, a setting with few durable treatment options.

The post Epitopea wins UK approval for therapeutic vaccine trial

According to the WHO, one adult in six ­globally is affected by infertility, but beyond this statistic,­ ­infertility is best understood as a couple’s problem, even when the under­lying biology sits with one partner. The way we currently ­handle infertility issues is more about bypassing biology through procedure, with in vitro fertilisation (IVF) as its backbone. But while I...

Swiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture.

The post R...

Belgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.

The post